États-Unis · Bourse & Finance · The Motley Fool

Viking Therapeutics' Oral Obesity Drug Advances to Phase 3 Testing. Is Now the Time to Buy This Biotech Stock?

Publié par The Motley Fool · États-Unis il y a 8 h

Viking's weight loss pill program has a couple of issues, including the fierce competitors who have a big head start.

Lire l'article complet sur The Motley Fool Connectez-vous pour sauvegarder

MediaNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.fool.com)

À lire aussi

Business Insider

I moved my family from Australia to New York City 12 years ago. It's led to some very expensive regrets.

China passenger vehicle retail market slumps 24% in September

Trump says he’s evaluating whether the U.S. should join Saudi Arabia’s fight against Iran-backed Houthi rebels in Yemen after fresh attacks on Riyadh

CFTC Draws the Line Between Prediction Markets and Gambling in New Rules

Petra Power looks to modernize energy for data centers and defense vehicles

Kasai, Klarity and 8 other baby names surging in America